Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 5/20 | 0.97 |
| ▸ | AVPR2 known ✓ | P30518 | 3/20 | 0.97 |
| ▸ | AVPR1B known ✓ | P47901 | 3/20 | 0.97 |
| ▸ | OXTR | P30559 | 8/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL1172203 | 1.00 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL1171610 | 0.99 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29387302 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22511 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29454824 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.94 | AVPR1A (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL31061295 | 0.93 | AVPR2 (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.92 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.92 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL17874853 | 0.92 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015331-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSIS | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-12102629-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | BELHAVEN BIOPHARMA, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118436582-A | Nasal preparation of high-efficiency broad-spectrum anti-coronavirus polypeptide and preparation method thereof | 北京悦康科创医药科技股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117513826-A | Outdoor single standing mini-enclosure mini-urinal public toilet for men and women and application thereof | 刘文泉 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024015331-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSIS | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230405350-A1 | UV THERAPY PROTOCOL FOR TREATMENT OF NON-DERMATOLOGICAL CHRONIC CONDITIONS | LumaVive LLC | 2023-12-21 | — | — | US | disclosed |
| US-11779777-B1 | UV therapy protocol for treatment of non-dermatological autoimmune conditions | LumaVive LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230047961-A1 | THE CHOLESTEROL-SYNTESIS INTERMEDIATES FOR TREATMENT DEMYELINATING DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-02-16 | — | — | US | disclosed |
| US-11433063-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | BELHAVEN BIOPHARMA, INC. (US) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433063-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | ACHE, CHRM3, CHRND | AVPR1A 615/4885AVPR2 427/4885AVPR1B 679/4885 |
| US-12102629-B1 | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides | ACHE, CHRM3, CHRND | AVPR1A 615/4885AVPR2 427/4885AVPR1B 679/4885 |
| US-20230047961-A1 | THE CHOLESTEROL-SYNTESIS INTERMEDIATES FOR TREATMENT DEMYELINATING DISORDERS | HMGCR, SGMS1, CETP | AVPR1A 4836/4885AVPR2 4851/4885AVPR1B 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.